C-TLNEgenerative AI, automation, drug discovery
0-100 chain-logic scale · 15 dimensions · scored on public evidence
Evaluate safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary antitumor activity in advanced or metastatic solid tumors.
First-in-human Phase 1a/b open-label multicenter dose escalation, optimization, and expansion study using ISM5939 monotherapy and combination therapy.
ClinicalTrials.gov record for Phase 1a/b study.
Evaluate safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary antitumor activity in advanced or metastatic solid tumors.
First-in-human Phase 1a/b open-label multicenter dose escalation, dose optimization, and dose expansion study of ISM5939 monotherapy and combination therapy.
ClinicalTrials.gov record describes a Phase 1a/b study in advanced and/or metastatic solid tumors.
Evaluate safety, tolerability, pharmacokinetics, and pharmacodynamics in healthy adults, elderly participants, and obese adults at risk of cardiovascular disease.
Single-center Phase 1 randomized, double-blind, placebo-controlled sequential single- and multiple-ascending oral dose study.
ClinicalTrials.gov record describes Phase 1 testing in healthy, elderly, and obese cardiovascular-risk participants.
Evaluate safety, tolerability, pharmacokinetics, and pharmacodynamics in healthy adults, elderly participants, and obese adults at risk of cardiovascular disease.
Single-center Phase 1 randomized, double-blind, placebo-controlled sequential study of single and multiple ascending oral doses.
ClinicalTrials.gov record for Phase 1 study.
Replace or generalize specialist aging clocks across biodata modalities and support drug discovery and aging research.
Qwen3-14B model fine-tuned with supervised and reinforcement learning on DNA methylation, proteomics, clinical biomarker, and RNA expression data as part of the Multi-Modal AI Gym for Science initiative.
BioRxiv interim report from the initial sprint of the Multi-Modal AI Gym for Science.
Reported high Longevity Bench ranks and 4.34-year MAE in epigenetic age prediction after reinforcement fine-tuning, surpassing the Horvath multi-tissue clock in the supplied abstract.
Explore and map chemical space around the clinically relevant NLRP3 target to identify diverse, patentable potential inhibitors.
Latent Enumeration, Generation, Integration, Optimization, and Navigation workflow integrating generative AI, AI-guided screening in Chemistry42, cheminformatics, pharmacophore-aware scaffold extraction, and library enumeration.
Published a dataset of approximately 110 million potential NLRP3 inhibitor molecular structures, expandable to 123 billion structures with provided code.
Identified over 34,000 unique scaffolds and produced a dataset useful for scaffold hopping, chemical-space navigation, and intellectual property support.
Evaluate safety, tolerability, pharmacokinetics, and clinical efficacy in adult patients with active ulcerative colitis.
Oral ISM5411 evaluated in a multicenter randomized, double-blind, placebo-controlled study; earlier healthy-volunteer study evaluated single and multiple oral doses.
BETHESDA active ulcerative colitis clinical study listed after healthy volunteer study.
Evaluate oral ISM5411 for active ulcerative colitis.
Multicenter randomized, double-blind, placebo-controlled clinical study assessing safety, tolerability, pharmacokinetics, and clinical efficacy; earlier healthy-volunteer study assessed single and multiple oral doses.
BETHESDA study in adult patients with active ulcerative colitis listed in ClinicalTrials.gov.
Evaluate safety and tolerability and determine the recommended Phase 2 dose in locally advanced or metastatic solid tumors.
Dose escalation and dose selection optimization clinical study.
ClinicalTrials.gov record for advanced/metastatic solid tumor study.
Evaluate safety and tolerability and determine recommended Phase 2 dose in locally advanced or metastatic solid tumors.
Clinical dose escalation followed by dose selection optimization.
ClinicalTrials.gov record describes dose escalation and RP2D selection in locally advanced/metastatic solid tumors.
Assess how strongly age-related diseases align with hallmarks of aging and prioritize disease-specific therapies with potential to translate into geroprotectors.
Disease scoring system and hallmark-alignment analysis of 13 aging-related diseases, with idiopathic pulmonary fibrosis identified as most aligned with aging.
Aging publication released a disease scoring system and hallmark alignment report.
The supplied abstract reports IPF as the disease most aligned with aging among 13 assessed age-related diseases.
Treat idiopathic pulmonary fibrosis, an age-related progressive lung disease, using a first-in-class AI-generated TNIK inhibitor.
Oral small-molecule TNIK inhibition evaluated in randomized placebo-controlled clinical trials in adults with IPF.
Phase 2a randomized trial reported; clinical trial records describe 12-week oral dosing studies in IPF.
Publication reports a first phase 2a multicenter, double-blind, randomized, placebo-controlled trial of rentosertib in IPF; related Aging and Disease paper reports senomorphic activity through reduction of SASP, reduced aging signatures, and effects on TGF-beta signaling.
Evaluate safety, tolerability, recommended Phase 2 dose, PK/PD, and preliminary antitumor activity in advanced or metastatic malignant mesothelioma or other solid tumors.
Phase 1 open-label multicenter first-in-human dose escalation and dose selection optimization study.
ClinicalTrials.gov record for Phase 1 first-in-human study.
Evaluate safety, tolerability, RP2D, PK/PD, and preliminary antitumor activity in advanced or metastatic malignant mesothelioma or other solid tumors.
Phase 1 open-label multicenter first-in-human dose escalation and dose selection optimization study.
ClinicalTrials.gov record describes Phase 1 first-in-human testing.
Evaluate safety and tolerability in participants with advanced solid tumors and relapsed or refractory B-cell lymphoma.
Clinical trial of orally administered ISM8207.
ClinicalTrials.gov record for advanced solid tumor and relapsed/refractory B-cell lymphoma study.
Evaluate safety and tolerability in advanced solid tumors and relapsed/refractory B-cell lymphoma.
Oral clinical trial of ISM8207 in oncology participants.
ClinicalTrials.gov record describes a study in advanced solid tumors and relapsed/refractory B-cell lymphoma.
Develop a therapy for a debilitating disease using Insilico's generative AI drug discovery platform.
Drug candidate discovered using Insilico's AI platform.
Reported by NVIDIA as entering Phase 2 clinical trials.
Develop a coronavirus-related therapeutic program targeting 3CLPro.
Target-based antiviral drug discovery program.
Listed in Insilico's therapeutic pipeline, which includes COVID-19 and coronavirus infection programs.
Develop a therapeutic program targeting 3CLPro.
AI-enabled drug discovery pipeline program.
Listed on Insilico Medicine's therapeutic pipeline.
Therapeutic pipeline program for diseases addressed by Insilico's drug discovery pipeline.
Target-based drug discovery program.
Listed in Insilico's therapeutic pipeline.
Develop a therapeutic program targeting CDK12.
AI-enabled drug discovery pipeline program.
Listed on Insilico Medicine's therapeutic pipeline.
Generate and optimize small-molecule drug candidates using generative AI.
Generative chemistry platform for AI-guided screening and molecule design.
Listed by Insilico as part of its drug discovery software suite; used in the LEGION NLRP3 inhibitor workflow.
Supported generation and screening of approximately 110 million potential NLRP3 inhibitor structures in the LEGION dataset.
Therapeutic pipeline program for diseases addressed by Insilico's drug discovery pipeline.
Target-based drug discovery program.
Listed in Insilico's therapeutic pipeline.
Develop a therapeutic program targeting DGKA.
AI-enabled drug discovery pipeline program.
Listed on Insilico Medicine's therapeutic pipeline.
Therapeutic pipeline program for diseases addressed by Insilico's drug discovery pipeline.
Target-based drug discovery program.
Listed in Insilico's therapeutic pipeline.
Develop a therapeutic program targeting ENPP1.
AI-enabled drug discovery pipeline program.
Listed on Insilico Medicine's therapeutic pipeline.
Therapeutic pipeline program for diseases addressed by Insilico's drug discovery pipeline.
Target-based drug discovery program.
Listed in Insilico's therapeutic pipeline.
Develop a therapeutic program targeting FGFR2/3.
AI-enabled drug discovery pipeline program.
Listed on Insilico Medicine's therapeutic pipeline.
Apply generative AI to biologics discovery and design.
AI software platform for biologics generation.
Listed by Insilico as part of its scientific research and drug discovery software suite.
Measure the potential of disease-specific therapies to translate into general geroprotective interventions.
Disease scoring system assessing hallmark alignment across 13 aging-related diseases.
Review released a disease scoring system and reported hallmark alignment for 13 aging-related diseases.
Idiopathic pulmonary fibrosis was reported as the disease most aligned with aging among the 13 diseases scored.
Support clinical development decision-making using AI.
AI software platform for clinical trial and development prediction or analysis.
Listed by Insilico as part of its software suite.
Therapeutic pipeline program for diseases addressed by Insilico's drug discovery pipeline.
Target-based drug discovery program.
Listed in Insilico's therapeutic pipeline.
Develop a therapeutic program targeting KAT6.
AI-enabled drug discovery pipeline program.
Listed on Insilico Medicine's therapeutic pipeline.
Therapeutic pipeline program for diseases addressed by Insilico's drug discovery pipeline.
Target-based drug discovery program.
Listed in Insilico's therapeutic pipeline.
Develop a therapeutic program targeting KIF18A.
AI-enabled drug discovery pipeline program.
Listed on Insilico Medicine's therapeutic pipeline.
Design and identify potential KRAS inhibitors for cancer therapy.
Quantum-classical generative model for small-molecule design, followed by selection and synthesis of proposed molecules.
Nature Biotechnology publication reported the design, selection, and synthesis of 15 proposed molecules targeting KRAS.
Two synthesized molecules were reported as holding promise for future development as KRAS inhibitors.
Explore chemical space around NLRP3 to identify novel, bioactive, patentable, and synthetically accessible potential inhibitors.
Latent Enumeration, Generation, Integration, Optimization, and Navigation workflow combining generative AI, AI-guided Chemistry42 screening, 3D pharmacophore-aware scaffold extraction, ligand- and structure-based design, and library enumeration.
Published dataset of approximately 110 million molecular structures of potential NLRP3 inhibitors.
The workflow identified over 34,000 unique scaffolds and can expand to a dataset of 123 billion molecular structures; the dataset supported scaffold hopping, chemical-space navigation, and intellectual property applications.
Replace or match specialist aging clocks across multiple biological data modalities and reason over aging-related biodata.
Qwen3-14B model fine-tuned through supervised and reinforcement learning on DNA methylation, proteomics, clinical biomarker, and RNA expression data.
Interim report from the initial sprint of the Multi-Modal AI Gym for Science.
Reported high ranks in Longevity Bench tasks, including cancer survival and RNA/proteome age prediction; after reinforcement fine-tuning, achieved 4.34-year MAE in epigenetic age prediction and outperformed frontier LLMs on proteomic profile generation.
Therapeutic pipeline program for diseases addressed by Insilico's drug discovery pipeline.
Target-based drug discovery program.
Listed in Insilico's therapeutic pipeline.
Develop a therapeutic program targeting MAT2A.
AI-enabled drug discovery pipeline program.
Listed on Insilico Medicine's therapeutic pipeline.
Build foundation models for drug discovery and aging research.
Research initiative producing multimodal AI models such as Longevity-LLM.
Initial sprint reported through the Longevity-LLM v0.1 preprint.
Longevity-LLM v0.1 is described as an interim report from the initiative.
Discover and develop structurally diverse potential NLRP3 inhibitors.
LEGION workflow integrating generative AI, AI-guided screening within Chemistry42, structure- and ligand-based design, pharmacophore-aware scaffold extraction, and library enumeration.
A preclinical NLRP3 inhibitor rights-splitting deal was reported; a Scientific Data publication described approximately 110 million molecular structures and a 123 billion-structure expandable dataset around NLRP3.
LEGION identified over 34,000 unique scaffolds and generated a dataset intended to support scaffold hopping, chemical-space navigation, and intellectual property applications.
Identify and prioritize therapeutic targets from omics and biomedical evidence for drug discovery.
AI target discovery and omics analysis platform using factors such as novelty, confidence, commercial tractability, druggability, and safety.
Offered as part of Insilico Medicine's software suite and demo edition in Insilico Medicine School target-identification course.
Reported as instrumental in identifying targets for cancer, ALS, COVID-19, and related diseases.
Provide Insilico Medicine's AI drug discovery software suite for transforming drug discovery and development.
Generative AI and automation software platform for drug discovery.
Listed on the company site as AI drug discovery software.
Transform drug discovery and development using generative artificial intelligence and automation.
Software platform suite including PandaOmics, Chemistry42, Generative Biologics, inClinico, and Science42:DORA for target discovery, chemistry generation, biologics generation, clinical prediction, and scientific assistance.
Insilico site lists Pharma.ai products and therapeutic programs discovered using generative AI and automation.
Therapeutic pipeline program for diseases addressed by Insilico's drug discovery pipeline.
Target-based drug discovery program.
Listed in Insilico's therapeutic pipeline.
Develop a therapeutic program targeting PHD.
AI-enabled drug discovery pipeline program.
Listed on Insilico Medicine's therapeutic pipeline.
Therapeutic pipeline program for diseases addressed by Insilico's drug discovery pipeline.
Target-based drug discovery program.
Listed in Insilico's therapeutic pipeline.
Develop a therapeutic program targeting QPCTL.
AI-enabled drug discovery pipeline program.
Listed on Insilico Medicine's therapeutic pipeline.
Support scientific research using Insilico's AI tools.
AI software product for scientific research workflows.
Listed by Insilico as part of its software suite.
Therapeutic pipeline program for diseases addressed by Insilico's drug discovery pipeline.
Target-based drug discovery program.
Listed in Insilico's therapeutic pipeline.
Develop a therapeutic program targeting TEAD.
AI-enabled drug discovery pipeline program.
Listed on Insilico Medicine's therapeutic pipeline.
Therapeutic pipeline program for diseases addressed by Insilico's drug discovery pipeline.
Target-based drug discovery program.
Listed in Insilico's therapeutic pipeline.
Develop an AI-discovered/generative-AI-designed small-molecule therapeutic for idiopathic pulmonary fibrosis, an aging-related disease.
Generative AI drug discovery leading to a randomized phase 2a multicenter, double-blind clinical trial.
Randomized phase 2a trial results reported in a publication.
Publication title reports a generative AI-discovered TNIK inhibitor for idiopathic pulmonary fibrosis in a randomized phase 2a trial; detailed outcome data were not supplied.
Therapeutic pipeline program, including oncology or other disease areas described in Insilico's pipeline.
Target-based drug discovery program.
Listed in Insilico's therapeutic pipeline.
Develop a therapeutic program targeting USP1.
AI-enabled drug discovery pipeline program.
Listed on Insilico Medicine's therapeutic pipeline.